Teva Mimvey Lo Tablets Recall: Impurity Risk in Estradiol/Norethindrone
Teva Pharmaceuticals USA recalls Mimvey Lo (estradiol and norethindrone acetate tablets) due to failed impurity tests. This medication may contain unsafe levels of norethindrone impurities. Consumers should contact Teva for details.
Recall notice
Failed Impurities/Degradation Specifications: out of specification test results for the norethindrone impurity.
Contact the company
What happened, in plain English
Teva Pharmaceuticals USA is recalling Mimvey Lo (estradiol and norethindrone acetate tablets) because tests found impurities in the medication. This could pose a risk to users, though the specific health impact isn't detailed in the recall notice. Read more at govinfonow.com/recall/42058-teva-mimvey-lo-tablets-recall-impurity-risk-in-estradiol-norethindrone.
Source Summary by GovInfoNow · govinfonow.com/recall/42058-teva-mimvey-lo-tablets-recall-impurity-risk-in-estradiol-norethindrone · Updated October 8, 2026 · FDA enforcement record: FDA #D-0479-2017
Cite this page
“Teva Mimvey Lo Tablets Recall: Impurity Risk in Estradiol/Norethindrone.” GovInfoNow, updated October 8, 2026. https://govinfonow.com/recall/42058-teva-mimvey-lo-tablets-recall-impurity-risk-in-estradiol-norethindrone. Based on FDA recall #D-0479-2017 (https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0479-2017%22&limit=1).
Why it’s dangerous
The recall states that the medication failed impurity tests, meaning it may contain unsafe levels of norethindrone. This could potentially cause health issues, but the specific risks aren't detailed in the recall notice.
Who’s affected
People who have the Mimvey Lo tablets with NDC 0093-5454-18 or 0093-5454-62, packaged in 3 blister cards per carton. Those taking this medication for birth control or hormone therapy are most at risk.
How to tell if you have this one
Check for Mimvey Lo tablets labeled 0.5 mg/0.1 mg, 28 tablets per blister card, with NDC 0093-5454-18 or 0093-5454-62. The product is prescription-only and packaged in 3 blister cards per carton.
- Brand
Teva Pharmaceuticals USA- Category
Drug
What to do — step by step
Contact Teva
Reach out to Teva Pharmaceuticals USA for specific instructions on what to do with the recalled product.
Where it went and when
Where it was distributed
Distributed nationwide.
FDA distribution: “Nationwide in the United States” States read from FDA’s own wording; “not listed” means the notice does not name it.
Distributed nationwide.
Recall timeline
FDA terminated this recall 12 months after the firm started it.
- Firm started the recall
- FDA classified it Class II
- Published in FDA’s Enforcement Report
- FDA terminated the recall
Dates from the agency record only; steps without a date are left out.
Similar recalls
Latest drug recalls
Keep exploring
Where this comes from
The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.
- Official source: FDA Recall #D-0479-2017 (February 2, 2017) — FDA publishes no per-recall page; this is the official machine-readable enforcement record. Search FDA recalls for D-0479-2017 to see it in context.
- Plain-language summary written by qwen3:4b on October 8, 2026, from the official record above. Not reviewed by a person — if it conflicts with the FDA notice, the notice is correct. Report an error on this page.
- GovInfoNow is an independent service and is not a government agency. We republish official FDA recall data; we don’t issue, amend or administer recalls.